Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Rubens

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Pituitary|December 25, 2014
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trialJochen Schopohl, Feng Gu, Robert Rubens, et al.
Journal of Parkinson'S Disease|October 8, 2015
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical TrialsPaul A Nausieda, Ann Hsu, Lawrence Elmer, et al.
Journal of the Neurological Sciences|January 30, 2017
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's diseaseJames Tetrud, Paul Nausieda, David Kreitzman, et al.
Digital Biomarkers|January 14, 2021
Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory ScienceDiane Stephenson, Robert Alexander, Varun Aggarwal, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Pituitary|December 25, 2014
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trialJochen Schopohl, Feng Gu, Robert Rubens, et al.
Journal of Parkinson'S Disease|October 8, 2015
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical TrialsPaul A Nausieda, Ann Hsu, Lawrence Elmer, et al.
Journal of the Neurological Sciences|January 30, 2017
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's diseaseJames Tetrud, Paul Nausieda, David Kreitzman, et al.
Digital Biomarkers|January 14, 2021
Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory ScienceDiane Stephenson, Robert Alexander, Varun Aggarwal, et al.
Pageof 3